GEN Exclusives

More »

GEN News Highlights

More »
Sep 20, 2006

Isis Pharmaceuticals Receives Patent for Pathogen Identification Method

  • Isis Pharmaceuticals was issued U.S. Patent 7,108,974, covering the identification of bacterial organisms obtained by analyzing molecular signatures derived from the organism’s DNA used in the Ibis T5000™ biosensor system.

    Using the Ibis T5000 biosensor system, developed and being commercialized by the company’s Ibis division, investigators can identify virtually any organism without spending too much time on culturing, sequencing, or hybridization steps, without even knowing which organisms might be present in the sample, according to Isis. It can be used to detect biowarfare threats, to identify sources of hospital-associated infections, to monitor emerging and pandemic diseases, and to characterize human samples for forensic applications, the company adds.

    Currently, three systems have been installed with government agencies. Ibis expects its first commercial system sale in 2006.

    “The new patent is the first of what we expect to be a growing portfolio of patents covering all of the key components of the Ibis T5000 system, including assay kits, hardware components, and data analysis software,” predicts Michael Treble, president of Ibis biosciences division.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

New NIH Budget Proposal Leaves Many Confused and Unsettled

Do you think that using the so-called “mandatory budget funds” to pay for the proposed $825 million increase, as well as $1 billion of the NIH’s existing budget is a good idea?

More »